Chlorhexidine - GlaxoSmithKline

Drug Profile

Chlorhexidine - GlaxoSmithKline

Alternative Names: Clorhexidine gel - GlaxoSmithKline; Umbipro

Latest Information Update: 04 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-infectives; Antiseptics; Biguanides; Small molecules
  • Mechanism of Action Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Infections

Most Recent Events

  • 29 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval (under Article 58 procedure) of Chlorhexidine gel (7.1% chlorhexidine digluconate gel, equivalent to 4% chlorhexidine) for Infections (in neonates) in markets outside EU
  • 16 Oct 2015 Phase-III clinical trials in Infections (In neonates) in Nepal (Topical) before October 2015 (GSK pipeline, March 2015)
  • 12 Oct 2015 Preregistration for Infections (In neonates) in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top